

4 December 2025

**Physiomics plc**  
("Physiomics" or the "Company")

**Physiomics Awarded Two New Contracts**

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the award of two new modelling and simulation contracts with the total value of £29,750.

**Contract Award 1:**

Physiomics has secured a contract with a UK-based biotech firm specialising in AI-powered drug development. Building on an earlier projects announced on 25 June 2025 and 6 August 2025, this new agreement is worth £13,600 and involves using Physiomics' unique Virtual Tumour Platform to guide dosing decisions for the client's leading oncology drug. The project is scheduled to complete within the next month.

**Contract Award 2:**

Physiomics has secured a contract in collaboration with a partner to support a UK-based biotech client in the development of renal disease therapies. Valued at £16,150, this project focuses on establishing a modelling and simulation strategy to advance the client's drug development efforts.

While future opportunities cannot be guaranteed, the Company anticipates that this initial engagement may lead to larger projects involving further execution of modelling and simulation initiatives for the client. Completion of this project is expected within the next month.

**Dr Peter Sargent, CEO of Physiomics, commented:**

*"We are thrilled to have secured these two contracts. Extending our agreement with an existing client (Contract Award 1) demonstrates the value we deliver and our strong rate of repeat business. Additionally, winning a contract with a new client (Contract Award 2) highlights both our commitment to continue diversifying our client base as well as expand into therapeutic areas beyond oncology".*

For more information about Physiomics and its services, please visit [www.physiomics.co.uk](http://www.physiomics.co.uk).

**Enquiries:**

**Physiomics plc**  
Dr Peter Sargent, CEO  
+44 (0)1235 841575

**Hybridan LLP (Broker)**  
Claire Louise Noyce  
+44 (0) 203 764 2341

**Strand Hanson Ltd (NOMAD)**  
James Dance & James Bellman  
+44 (0)20 7409 3494

## Notes to Editor

### About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRATJBBTMTJMBLA